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Background: Recent studies have confirmed the presence of viable Chlamydia in the bronchoalveolar lavage (BAL)
fluid of pediatric patients with airway hyperresponsiveness. While specific IgG and IgM responses to C. pneumoniae
are well described, the response and potential contribution of Ag-specific IgE are not known. The current study
sought to determine if infection with Chlamydia triggers the production of pathogen-specific IgE in children with
chronic respiratory diseases which might contribute to inflammation and pathology.
Methods: We obtained BAL fluid and serum from pediatric respiratory disease patients who were generally
unresponsive to corticosteroid treatment as well as sera from age-matched control patients who saw their doctor
for wellness checkups. Chlamydia-specific IgE was isolated from BAL and serum samples and their specificity
determined by Western blot techniques. The presence of Chlamydia was confirmed by species-specific PCR and BAL
culture assays.
Results: Chlamydial DNA was detected in the BAL fluid of 134/197 (68%) patients. Total IgE increased with age until
15 years old and then decreased. Chlamydia-specific IgE was detected in the serum and/or BAL of 107/197 (54%)
patients suffering from chronic respiratory disease, but in none of the 35 healthy control sera (p< 0.0001). Of the 74
BAL culture-positive patients, 68 (91.9%, p=0.0001) tested positive for Chlamydia-specific IgE. Asthmatic patients had
significantly higher IgE levels compared to non-asthmatics (p= 0.0001). Patients who were positive for Chlamydia
DNA or culture had significantly higher levels of serum IgE compared to negative patients (p= 0.0071 and
p= 0.0001 respectively). Only 6 chlamydial antigens induced Chlamydia-specific IgE and patients with
C. pneumoniae-specific IgE had significantly greater levels of total IgE compared to C. pneumoniae-specific IgE negative
ones (p=0.0001).
Conclusions: IgE antibodies play a central role in allergic inflammation; therefore production of Chlamydia-specific
IgE may prove significant in the exacerbation of chronic, allergic airway diseases, thus highlighting a direct role for
Chlamydia in asthma pathogenesis.
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Inflammation of the airways is the most common finding
in all asthma patients and today, most asthma experts
consider airway inflammation a central feature of asthma
pathogenesis [1,2]. The genetic predisposition to asthma
development has been well recognized and the IgE-
mediated response to common aero-allergens represents
the most common form of the disease in childhood and
early adulthood [3]. Published evidence strongly suggests
a relationship between microbes and asthma [4]. It has
long been known that the most potent triggers of wheez-
ing are mediated by viruses, however, we do not under-
stand the mechanisms involved in how they contribute
to disease onset and progression. Even less is known
about the relationship between asthma and bacteria. Re-
cent studies confirm that bacterial respiratory infections
are frequently associated with increased airway obstruc-
tion in patients with bronchial asthma [3]. While the hy-
giene hypothesis predicts that infections in early life by
non-pathogenic microbes should protect against asthma
and atopy [5], there is increasing evidence that certain
chronic pathogenic infections might also promote airway
hyperresponsiveness and asthma development or exacer-
bation [6-8].
Approximately 20% of wheezing children have sero-
logical evidence of an immune response to Streptococcus
pneumoniae, Haemophilus influenzae and Moraxella
catarralis [9,10]. More recently, Mycoplasma pneumo-
niae and Chlamydia pneumoniae have been identified in
5–25% of children with asthma exacerbations [11-13].
Hahn et al also reported a significant improvement in
overall asthma symptoms at treatment completion which
persisted for 3 months despite withdrawal of azithromy-
cin in an adult population [14,15].
Earlier studies by Welliver et al. [16] reported IgE
responses to RSV in children with bronchiolitis and
showed that this IgE response was related to recurrent
wheeze, but not to lung function and allergic sensitization
at an early age. This suggests that IgE antibodies to RSV
occur independently of atopy and may be indicative of
an ongoing asthmatic process. Specific IgE to bacterial
colonizers has also been reported. H. influenzae and
S. pneumoniae specific IgE antibodies have been found
in the serum of approximately a third of atopic children
and asthmatic adults, however, they were all related to a
subject’s atopic status [17]. The implication here is that
IgE has a complex relationship with asthma that might
not be dependent on the specific allergens that are rou-
tinely assayed for [18].
In the current study we examined the BAL fluid and
serum of a large cohort of children with chronic respira-
tory disease for the presence of Chlamydia-specific IgE
antibodies. We hypothesize here that the presence of
Chlamydia-specific IgE antibodies explains, at least inpart, the mechanism of chlamydial involvement in either
initiating or exacerbating chronic allergic airway disease.
Methods
Patients and samples
Serum and BAL samples were analyzed from 197
patients between the ages of 0–20 who were patients at
Baystate Medical Center. BAL samples were originally
obtained from patients for diagnostic or treatment pur-
poses. Children were considered for bronchoscopy only
after a thorough, non-invasive evaluation did not yield a
definitive diagnosis; symptoms were not improving with
time; aggressive medical management had not been suc-
cessful and the child was truly compromised i.e., was
missing school, could not participate in physical activity
and had frequent symptoms. Airway reactivity was mo-
nitored by spirometry in children capable of performing
the test as well as clinically, by frequency and severity of
symptoms and response to therapy. In children not
capable of performing spirometry, clinical characteristics
were assessed.
We also obtained 35 age and gender-matched control
patient sera as residual samples from patients undergo-
ing wellness check for school records or general checkup
at the University of Massachusetts Health Services com-
plex over a similar period of time as the patient samples.
We obtained IRB approval and patient consent to collect
and use these residual samples for research from the
Baystate Medical Center and University of Massachu-
setts Amherst IRB. In addition, a subset of 20 (of the
197) respiratory disease patients presented with physical
airway anomalies including most commonly, tracheal
bronchus, obstruction by a foreign object, laryngomala-
cia, tracheomalacia, and bronchomalacia with abnormal
cough. These were considered non-inflammatory con-
trols when compared with asthmatics and patients with
pneumonia and bronchitis.
Chlamydia detection in patient samples
Genomic DNA was isolated from BAL samples and PCR
detection of chlamydial DNA was performed in the same
manner as previously described for all samples in this
cohort [19]. All BAL samples were also analyzed by tis-
sue culture techniques to determine Chlamydia viability
as previously reported [12,19]. DNA was also isolated
from control serum samples in a similar manner as the
BAL and evaluated using the same primers.
Total IgE evaluation
Total IgE was evaluated using the Elecsys IgE kit (Roche
Diagnostics, Indianapolis, IN), with the electrochemilu-
minescence immunoassay according to the manufac-
turer’s instructions. Plates were read on the Roche
Elecsys 1020 analyzer which automatically calculated the
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curve. Elevated IgE levels were determined based on the
manufacturer’s recommended threshold by age range.
Isolating serum and BAL IgE antibodies
Because the normal concentration for IgE in serum is
approximately 0.0005 mg/ml, and is even less in BAL
fluid, we utilized affinity beads in a similar manner as
Kadooka et al [20] to isolate the IgE antibodies in order
to ensure effective reaction of these antibodies with chla-
mydial antigens on our blots. We used recombinant Pro-
tein G sepharose gel (Sigma-Aldrich, St. Louis, MO) to
adsorb IgG antibodies from the serum samples. Since re-
combinant protein G does not bind IgE antibodies
[21,22], individual patient serum samples were added to
the beads and allowed to bind with slow stirring over-
night. The supernatant that was now ‘enriched’ for IgE
antibodies was then removed and analyzed for the pre-
sence of Chlamydia-specific IgE antibodies.
To test for IgE in BAL samples, recombinant protein
A beads (Sigma-Aldrich, St. Louis, MO) were utilized in
the same manner as the protein G beads above. In this
case the protein A beads were used to adsorb any anti-
bodies detectable in the BAL fluid. IgE antibodies
present in the BAL fluid were bound by the protein A
beads and the bound antibodies were eluted using a pH
2.5 glycine solution followed by centrifugation to obtain
the supernatant containing IgE and other antibodies if
present. The eluted antibodies were pH balanced using
Tris–HCl and then used as the primary antibody in the
Western blot procedure. Because of the limited volume
of some BAL fluid samples available and the low con-
centration of IgE in each sample, BAL samples were ini-
tially assessed in batches of 4 to 7 samples each.
Western blot procedure
As previously reported, Western blot is a highly sensitive
and efficient technique in detecting specific IgE [23-25].
C. pneumoniae (TW183) and C. trachomatis (serovar E)
elementary bodies were purified by 20%–50% (vol/vol)
Renografin gradient centrifugation as previously described
[26] and normalized for protein content using the
Bradford protein assay. Proteins were separated by elec-
trophoresis on NuPage 4–12% Bis Tris gels (Invitrogen,
Carlsbad, CA). Following electrophoresis the separated
proteins were transferred to PVDF membranes, blocked
and each well was cut into individual strips. Each
strip was incubated with patient sample that had been
processed with protein A or G beads overnight. After
incubation, the strips were washed and a 1:500 dilu-
tion of AP-conjugated anti-human IgE, epsilon chain spe-
cific antibody (KPL, Gaithersburg, Maryland) was added
to each strip for 2 hours. Strips were again washed
and developed with a BCIP/NBT alkaline phosphatasesubstrate and reactions were stopped after several
washes with ultrapure distilled water. Blot strips were
analyzed for the presence and identity of Chlamydia-
specific IgE bands. All samples were assayed for the
presence of specific IgE using identical conditions in-
cluding sample dilution.
Cell counts
BAL cell counts and differentials were performed accor-
ding to standard techniques in the hospital’s Hematology
Clinical Laboratory at Baystate Medical Center (Springfield,
MA) as previously reported [19,27]. Briefly, cell enumer-
ation was performed manually using a cell counting
chamber under phase microscopy with results expressed
as “number of cell/mm3. BAL differential counts were
performed using Wright stained cytospin preparations
of BAL and examination was performed under oil-
immersion microscopy (50X or 100X). Results were
expressed on the basis of a 100 cell count survey. In-
flammatory asthma sub-phenotypes were determined
based on BAL neutrophil and eosinophil cells counts, as
previously reported [28].
Statistical analysis
All statistical analyses among the different groups of the
patient population were performed using Microsoft
ExcelW. Statistical correlations were determined with
Fisher’s exact test and Chi-square with Yates correction
(SPSS 15.0 software). A p-value of 0.05 was considered
significant and all tests were two-tailed.
Results
Characteristics of study patients
We obtained both BAL fluid and serum from 197
pediatric respiratory disease patients, average age 7.9
years old, who presented to a pediatric pulmonary prac-
tice in Springfield, MA with chronic respiratory disease
and were generally unresponsive to corticosteroid treat-
ment. The patient demographic (Table 1), shows that
143/197 (73%) were diagnosed with asthma and that
these asthmatics were predominantly between the ages
of 2 to 10 years old. We utilized a healthy control group
of 35 patients, average age 5.8 years, 21 males/14
females who saw their doctors for wellness checks.
Total serum IgE generally increased with age up to 15.0
years old (40 IU/ml to 250 IU/ml; see Figure 1). The
levels decreased significantly in the 15.1 to 20.0 year old
age group.
Prevalence of Chlamydia in patient cohort
Polymerase chain reaction (PCR) was utilized to deter-
mine if C. trachomatis and/or C. pneumoniae organisms
were present in patient BAL samples. A total of 134/197
(68%) patient samples were positive for chlamydial







Diagnosis 143 (72.6%) 54 (27.4%) 197
Average age 8.3 7.1 7.9
Age range
0-2.0 14 (9.8%) 16 (29.6%) 30
2.1-5.0 38 (26.6%) 13 (24.1%) 51
5.1-10.0 41 (28.7%) 8 (14.8%) 49
10.1-15.0 29 (20.3%) 9 (16.7%) 38
15.1-20.0 21 (14.6%) 8 (14.8%) 29
Gender
Female 65 (45.5%) 25 (46.3%) 90
Male 78 (54.5%) 29 (53.7%) 107
Ethnicity
White 107 (74.8%) 43 (79.6%) 150
Black 7 (4.9%) 4 (7.4%) 11
Hispanic 29 (20.3%) 6 (11.1%) 35
Asian 0 (0.0%) 1 (1.9%) 1
BMTH
Yes 118 (82.5%) 17 (31.5%) 135
No 10 (7.0%) 18 (33.3%) 28
Not Done 15 (10.5%) 19 (35.2%) 34
Most of the patients in this cohort were asthmatics (72.6%) with an average
age of 8.3 years old (7.9 years old for entire cohort). The majority of asthma
patients were between ages 2 to 10 years old and basement membrane
thickening (BMTH) was significantly correlated with asthma diagnosis.
Figure 1 Total Serum IgE levels generally increased with age. Assessm
to age 15.0 years old (40 IU/ml to 250 IU/ml). The levels then decreased to
range.
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were positive for C. pneumoniae DNA only, 34 were
positive for C. trachomatis DNA only and 35 patients
harbored both C. trachomatis and C. pneumoniae DNA.
In order to determine if the organisms detected by PCR
were viable, all BAL samples were subjected to a modi-
fied tissue culture technique as previously described.
The data showed that 74/197 (38%) patients assayed
were culture positive for Chlamydia. Importantly, 62/74
(84%, (Fisher’s exact test p< 0.0001) culture positive
patients were diagnosed with chronic, severe asthma
according to GINA guidelines [29]. Analyses of the con-
trol patient sera revealed that 7/35 (20%) were positive
for the presence of chlamydial DNA.Total IgE antibody serum levels
Data analysis revealed that 65/197 (33%) patients had ele-
vated serum IgE levels, while 132/197 (67%) had normal
IgE levels (Fisher’s exact T-test p< 0.0001). Patients who
were positive for Chlamydia by DNA or culture had sig-
nificantly higher levels of total serum IgE compared to IgE
negative patients (p=0.0071 and p=0.0001 respectively;
Figure 1). Patients who tested positive for C. pneumoniae
specific IgE antibodies also had an average IgE level that
was higher than the specific IgE negative cohort. Total
serum IgE generally increased with age up to 15.0 years
old (40 IU/ml to 250 IU/ml; see Figure 2). The levels
decreased significantly in the 15.1 to 20.0 year old age
group.ent of total serum IgE levels showed a general increase with age up
100IU/ml. Dark lines represent the average IgE level for each age
Figure 2 Presence of Chlamydia organisms is associated with higher levels of serum IgE. While the average total serum IgE levels in this
patient cohort was not significantly elevated (138 IU/ml), IgE levels were significantly more elevated in patients who were either Chlamydia DNA
positive or who had viable organisms as determined by culture. Patients with C. pneumoniae-specific IgE also had an average total IgE level that
was higher than their C. pneumoniae-negative counterparts. Horizontal dark bars represent the average IgE level and each shape in the respective
columns represents a single patient.
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serum of infected patients
In light of the increased prevalence of chlamydial orga-
nisms in the BAL fluid of patients in this cohort, patient
serum and BAL samples were analyzed to determine the
response of the host to the organism in each case and to
determine if there is pathology associated with its pre-
sence. We therefore developed a Western blot assay to
determine the presence, prevalence and identity of
Chlamydia-specific IgE in both the serum and BAL fluid
from each patient. Since BAL samples were assessed in
batches of 4 to 7 samples each (because of limited sample
volume), we cannot ascertain the exact percentage of
patients with Chlamydia-specific IgE in their BAL fluid.
However, qualitatively, BAL fluid samples from this pa-
tient cohort contained Chlamydia-specific IgE anti-
bodies (Figure 3). To our knowledge, this is the first
report of pathogen-specific IgE in human BAL fluid.
Chlamydia-specific IgE was also detected in the sera
of 107/197 (54%) patients suffering from chronic respira-
tory disease but none of the healthy control patient sera
(0/35, p< 0.0001). In addition, a subset of 20 patient
samples from our respiratory disease cohort who were
diagnosed with structural anomalies rather than inflam-
matory airway disease, were also assessed for the preva-
lence of Chlamydia-specific IgE. The data shows that
1/20 (5%) had Chlamydia-specific IgE in their sera
compared to the inflammatory patient cohort (Table 2).
Assessment to determine the prevalence of Chlamydia-
specific IgE antibodies in the BAL culture-positive patient
cohort showed that 68/74 (91.9%, p=0.0001) tested posi-
tive for Chlamydia-specific IgE.
Both C. trachomatis and C. pneumoniae-specific IgE
antibodies were found in the BAL fluid (Figure 4).Importantly, although Chlamydia has 800–1000 coding
genes, only 6 chlamydial antigens appear to induce
pathogen-specific IgE responses in this patient cohort and
the frequency of these bands differ significantly between
C. trachomatis and C. pneumoniae (Figure 4B and 4C). In
fact, most of the patient samples contained IgE antibodies
to a single protein band on the blots (see Figure 3).
Overall, 61% of the Chlamydia-specific IgE antibodies
in BAL fluid recognized the chlamydial major outer
membrane protein (MOMP). This was generally true
however, for C. pneumoniae IgE antibodies, where 81%
of the positive patients had IgE that recognized MOMP,
compared to only 17% for C. trachomatis MOMP. Thirty
three percent of BAL fluid positive patient samples dis-
played IgE antibodies against an un-annotated 250kDa
C. trachomatis protein.
Assessment of individual serum samples for the pre-
sence of Chlamydia-specific IgE antibodies revealed
bands on Western blot ranging in molecular weight
from 6kDa to 250kDa (Figure 5A). As was true for the
IgE antibodies in the BAL fluid, the identity of serum
IgE antibodies produced in response to C. trachomatis
were significantly different from C. pneumoniae – specific
antibodies (Figure 5B and C). Antigen frequency analysis
revealed that 42% of IgE positive serum samples contained
IgE antibodies that recognized C. pneumoniae chlamydial
lipopolysaccharide (cLPS). C. trachomatis - induced cLPS
IgE antibodies were not detected in any serum sample.
C. pneumoniae did not induce MOMP-specific IgE in
serum, while 8% of IgE positive-patients had antibodies
that recognized C. trachomatis MOMP (Figure 5C). There
were also significant differences in the production of
Chlamydia-specific IgE in the serum versus BAL fluid.
Chlamydial heat shock protein 60 (Hsp 60 or GroES) and
Figure 3 Western blot of Chlamydia-specific IgE. The blots depict
representative patient BAL and serum samples that were positive for
the presence of Chlamydia-specific IgE. Band specificities were
determined by a Chlamydia-positive control and the Chlamydia
protein data-base was used to confirm the corresponding protein.
Note that of all the chlamydial proteins seen on the control strip
stained with a polyclonal antibody solution, only a finite number are
recognized by specific IgE antibodies.
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not induce IgE antibodies in the BAL fluid, however, they
each accounted for the Chlamydia-specific IgE found
in 20% of positive patient sera assayed. The frequency of
MOMP-induced IgE in the BAL fluid was 61%, while
the frequency in serum was only 5%, demonstrating
possible site-specific differential cytokine and lymphocyte
responses or antibody release (see Figures 4A and 5A).
Inflammatory asthma phenotype and serum IgE
concentrations
Eosinophilic inflammation, characterized by high levels of
eosinophils, atopy and elevated serum IgE concentration,
has long been considered one of the most distinctive
pathological hallmarks of asthma [30]. However, it has re-
cently been recognized that airway eosinophilia is not aTable 2 The prevalence of Chlamydia-specific IgE in Patient S
Respiratory disease Non-inflamm
Number of Patients 177 20
Serum IgE, No. (%)
Positive 97 (55%) 1 (5%)
Negative 80 (45%) 19 (95%)
Chlamydial DNA, No. (%)
Positive 124 (70%) 10 (50%)
Negative 53 (30%) 10 (50%)
Fifty five percent of patients with inflammatory respiratory disease had Chlamydia-s
structural anomalies and 0% of healthy controls (p= 0.0030 and 0.0001 respectively
chlamydial DNA, whereas only 20% of healthy controls tested positive for chlamydiuniversal finding and a significant subset of patients with
refractory asthma display a non-eosinophilic phenotype.
BAL cell counts revealed that 115/143 (80%) asthma
patients in this cohort presented with a non-eosinophilic
inflammatory asthma phenotype. Overall, the majority of
patients in this cohort 166/197 (84%) had normal BAL eo-
sinophil counts. Asthmatic patients had a significantly
higher total IgE level compared to non-asthmatic patients
and patients with an eosinophilic asthma phenotype had
significantly higher total serum IgE levels than other in-
flammatory asthma groups (p=0.0001; see Figure 6).Discussion
The nature of the clinical association that exists between
Chlamydia airway infection and subsequent develop-
ment of asthma in young children remains controversial.
In an effort to find discriminative serological or bio-
logical markers to differentiate between patients with
infection-mediated airway responsiveness and those with
other aeroallergen-specific disease, we utilized Western
blot techniques to determine and compare the Chlamydia-
specific IgE response in the sera of 197 pediatric patients
with chronic, severe respiratory disease.
The development of pathogen-specific IgE antibodies is
not unique to Chlamydia infection. Numerous reports
have demonstrated production of specific IgE antibodies
in response to infection by pathogens, including a variety
of viruses [31-33] and Mycoplasma [34]. Emre et al, pre-
viously reported the presence of C. pneumoniae-specific
IgE in a cohort of children with chronic respiratory dis-
ease, and suggested that production of specific IgE may be
an underlying mechanism leading to reactive airway dis-
ease in some patients with C. pneumoniae infection [35].
With our larger cohort, our data is in line with this pre-
vious report and is strongly predictive of severe reactive
airway disease and poor asthma outcome. To this end,
while the role of pathogen-specific IgE antibodies has still
not been fully determined, when studied, in most cases, the
responses were associated with a poorer prognosis [33].era
atory disease P-values Healthy controls P-values
35
0.0030* 0 (0%) 0.0001*
35 (100%)
0.4417 7 (20%) 0.0208*
28 (80%)
pecific IgE antibodies in their sera compared to 5% of the 20 patients with
. 70% of the patients diagnosed with respiratory disease also tested positive for
al DNA (p= 0.0208).
Figure 4 Chlamydia protein molecular weight frequency trends in BAL fluid. Chart A shows the overall molecular weight of proteins
recognized by Chlamydia-specific IgE antibodies from patient BAL samples. These are for C. trachomatis and C. pneumoniae specific antibodies
combined. The major outer membrane protein (MOMP) is recognized 61% of the time by these positive patient sera. However, chart B clearly
shows that the MOMP from C. pneumoniae organisms were more likely to induce IgE antibodies than C. trachomatis MOMP (Chart C). The
hypothetical 250KDa protein was the most frequently recognized C. trachomatis protein in BAL.
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current study harbored chlamydial DNA and 54% pro-
duced detectable levels of specific IgE antibodies in re-
sponse to chlamydial infection. Age matched, healthy
controls had no detectable Chlamydia-specific IgE in their
serum. There was also a significant association between
the presence of Chlamydia-specific IgE antibodies in theFigure 5 Chlamydia protein molecular weight frequency trends in Ser
against MOMP only appeared in 5% of the patients tested, while the other
Closer analysis shows that while serum IgE antibodies recognized C. pneum
was recognized by these samples (Chart C). Although MOMP is the major a
induce serum IgE production in this study.serum and cultivable Chlamydia from BAL fluid, suggest-
ing that the presence of viable, actively replicating orga-
nisms are more likely to induce pathogen-specific IgE
production and could therefore lead to greater allergic
type pathology. A limitation of the current study however,
is that we were not able to assess individual BAL samples
for the presence of Chlamydia-specific IgE because ofum. Unlike the BAL fluid proteins in Figure 2, serum IgE antibodies
5 antigens appeared at similar frequency to that of the BAL (Chart A).
oniae LPS in 42% of positive samples (Chart B), no C. trachomatis LPS
ntigen on the chlamydial EB surface, C. pneumoniae MOMP did not
Figure 6 Asthma phenotypes and total serum IgE levels. Asthmatic patients had significantly higher total IgE levels compared to non-asthmatic
patients. Inflammatory asthma phenotypes determined by BAL cell counts revealed that eosinophilic asthmatics had higher IgE levels compared to
non-eosinophilic phenotypes (neutrophilic, paucigranulocytic and mixed granulocytic patients).
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data on BAL IgE from pools of 4–6 samples. However, we
assessed individual serum samples that showed similar
banding patterns as the pooled BAL samples. A second
limitation is that our control cohort consisted of only 35
patients and we did not obtain BAL samples from these
patients since this is a highly invasive procedure. These
patients were not assessed clinically for any respiratory
disease since they appeared healthy upon physical
examination as part of a wellness checkup by a primary
care physician. However, compared to the respiratory
disease population, these healthy controls did not have
Chlamydia-specific IgE antibodies in their sera, suggesting
that this phenomenon is specific to a chronic, severe, re-
spiratory disease.
Chlamydial antigens recognized by specific IgE anti-
bodies were significantly different in the BAL and
serum for C. trachomatis versus C. pneumoniae. It is
not clear at the present time why these dramatic differ-
ences in antigen recognition exist. However, only 6
chlamydial antigens were recognized by either BAL or
serum specific IgE in this patient cohort. The only ob-
vious unique quality about these antigens is that they
are surface exposed or secreted by the organism. We
have assessed these proteins by utilizing reducing and
non-reducing SDS-PAGE conditions with the same
results. We confirmed the identity of the MOMP pro-
tein and the cLPS antigen using recombinant proteins
but used the Chlamydia protein data base to match the
most likely molecular weight for the other antigens.
Further assessment of the patient cohort for the pre-
sence and level of total IgE confirmed that only 31% of
patients who had Chlamydia-specific IgE had an overall
elevated IgE level. This strongly suggests that patients
who are assessed as non-atopic may nonetheless pro-
duce Chlamydia-specific IgE, which we hypothesize,
could lead to airway pathology.The primary biological function of IgE is to provide
immunity against multicellular parasitic pathogens [36].
However, in developed countries with good sanitation
where parasitic diseases are rare, IgE responses are most
often directed against innocuous allergens resulting in
type I allergic disease. Mouse-model studies have con-
sistently demonstrated that inhalation of innocuous
aerosolized protein antigens typically does not induce
antigen-specific Th2 responses leading to IgE production
[37]. However, it has been demonstrated that ongoing
Th2 responses produced either by antigen challenge or
infection during antigen inhalation can prevent the es-
tablishment of aerosol-induced IgE tolerance and lead
instead to Th2 priming [38]. It is possible as suggested
by Hollams et al [39], that upon bacterial infection
Th2 cytokines may just be suppressing other pro-
inflammatory cytokines, such as tumor necrosis factor-α
and IL-1, as well as mediators such as prostaglandin,
hence, counter-regulating the increased Th1 immune
responses. However, since C. pneumoniae surface antigens
have to be processed and presented by antigen presenting
cells (APC) to activate T-cells and, thus, may not directly
induce a Th2 response, this theory might not hold true in
this case.
Conclusions
C. pneumoniae has long been implicated in the inflam-
matory response experienced by chronic asthmatics;
however, a specific mechanism of its involvement has
remained elusive. While the role and regulation of IgE
antibodies towards microbial antigens is far from being
elucidated, results from the current study strongly sug-
gest that this obligate intracellular pathogen can induce
pathogen-specific IgE production and could therefore
lead to mast cell degranulation and release of vasoactive
agents. The presence of Chlamydia-specific IgE in the
serum would suggest that the organisms play a direct
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IgE, since unlike most aeroallergens that a patient can
avoid, the chlamydial organisms reside in the lower
airways and are continuously secreting bacterial anti-
gens. In addition, even if the organism is cleared by
antibiotic use or natural immune responses, Chlamydia –
specific IgE antibodies might still play an important role
in the development of exaggerated airway responsiveness
during subsequent subclinical or even asymptomatic
infection.
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